Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05503732
Other study ID # 21-012902
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date June 2024

Study information

Verified date September 2023
Source Mayo Clinic
Contact Rochester Cardiovascular Research Unit Preventive Team
Phone 507-538-7425
Email RSTCVRUPrevent@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn about the change in quality of sleep, structural organization of sleep, and cardiovascular responses after consuming an energy drink compared to a placebo drink with no caffeine or stimulants.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults 18 years of age and older. - Healthy subjects without known cardiovascular disease and thyroid disease. - Subjects who are on no medications (except oral contraceptive pill). - Nonsmokers. - No prior history of caffeine sensitivity or allergy. Exclusion Criteria: - Subjects with known cardiovascular or thyroid disease. - Subjects currently taking medications other than oral contraceptive pill. - Smokers. - Prior history of caffeine sensitivity or allergy. - Pregnancy. - Subjects who regularly consume energy drinks. - Subjects who typically go to sleep after midnight. - Subjects who traveled across 2 time zones in the last 7 days. - Shift workers. - Subjects who have or are suspected to have sleep apnea. - Subjects who have a body mass index > 35kg/m^2.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Energy Drink
Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
Placebo Drink
Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed

Locations

Country Name City State
United States Mayo Clinic Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in resting heart rate Seated heart rate Baseline and AM of day 2
Other Changes in resting blood pressure Seated systolic and diastolic blood pressure Baseline and AM of day 2
Primary Changes in sleep efficiency Time asleep / time in bed Throughout duration of sleep on both nights (night 1 and night 2)
Primary Changes in sleep continuity Frequency of wakefulness after sleep initiation Throughout duration of sleep on both nights (night 1 and night 2)
Primary Changes in sleep architecture Time spent in each stage of sleep Throughout duration of sleep on both nights (night 1 and night 2)
Primary QT segment QT duration Baseline, approximately 1 hour prior to energy drink consumption
Primary QT segment QT duration Throughout duration of sleep on both nights (night 1 and night 2)
Primary Atrial arrhythmias Frequency of ectopic atrial beats Baseline, approximately 1 hour prior to energy drink consumption
Primary Atrial arrhythmias Frequency of ectopic atrial beats Throughout duration of sleep on both nights (night 1 and night 2)
Primary Ventricular arrhythmias Frequency of ectopic ventricular beats Baseline, approximately 1 hour prior to energy drink consumption
Primary Ventricular arrhythmias Frequency of ectopic ventricular beats Throughout duration of sleep on both nights (night 1 and night 2)
Secondary Sympathetic activation quantified by changes in plasma norepinephrine Plasma norepinephrine while supine Baseline and AM of day 2
Secondary Sympathetic activation quantified by changes in plasma epinephrine Plasma epinephrine while supine Baseline and AM of day 2
Secondary Sympathetic activation quantified by changes in plasma dopamine Plasma dopamine while supine Baseline and AM of day 2
Secondary Sympathetic activation quantified by urine norepinephrine Total urine norepinephrine secretion Approximately 24 hours
Secondary Sympathetic activation quantified by urine epinephrine Total urine epinephrine secretion Approximately 24 hours
Secondary Sympathetic activation quantified by urine dopamine Total urine dopamine secretion Approximately 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links